BioNTech raised its full‑year sales guidance after receiving a milestone payment from Bristol Myers Squibb tied to their PD‑1xVEGF bispecific collaboration. The company cited the payment and stronger than expected commercial performance as drivers for the upward revision in its third‑quarter update. Management highlighted the deal economics with BMS and the contribution to near‑term cash flow, while reiterating investment in pipeline programs. The guidance bump underscores partnership revenues’ capacity to materially affect biotech quarterly outlooks.